
Regulatory T cells (Tregs) can eliminate autoreactive lymphocytes, induce self-tolerance, and suppress the inflammatory response. Mitochondria, as the energy factories of cells, are essential for regulating the survival, differentiation, and function of Tregs. Studies have shown that patients with autoimmune diseases of the central nervous system, such as multiple sclerosis, neuromyelitis optica spectrum disorder, and autoimmune encephalitis, have aberrant Tregs and mitochondrial damage. However, the role of mitochondrial-regulated Tregs in autoimmune diseases of the central nervous system remains inconclusive. Therefore, this study reviews the mitochondrial regulation of Tregs in autoimmune diseases of the central nervous system and investigates the possible mitochondrial therapeutic targets.
Obesity, a burgeoning global health issue, is increasingly recognized for its detrimental effects on the central nervous system, particularly concerning the integrity of the blood-brain barrier (BBB). This manuscript delves into the intricate relationship between obesity and BBB dysfunction, elucidating the underlying phenotypes and molecular mechanisms. We commence with an overview of the BBB's critical role in maintaining cerebral homeostasis and the pathological alterations induced by obesity. By employing a comprehensive literature review, we examine the structural and functional modifications of the BBB in the context of obesity, including increased permeability, altered transport mechanisms, and inflammatory responses. The manuscript highlights how obesity-induced systemic inflammation and metabolic dysregulation contribute to BBB disruption, thereby predisposing individuals to various neurological disorders. We further explore the potential pathways, such as oxidative stress and endothelial cell dysfunction, that mediate these changes. Our discussion culminates in the summary of current findings and the identification of knowledge gaps, paving the way for future research directions. This review underscores the significance of understanding BBB dysfunction in obesity, not only for its implications in neurodegenerative diseases but also for developing targeted therapeutic strategies to mitigate these effects.
Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducted an indirect treatment comparison to compare the efficacy and safety of CGRP monoclonal antibody with botulinum toxin for the preventive treatment of chronic migraine.Methods: Up to August 31, 2020, we systematically searched PubMed, Embase, and Cochrane Library Central Register of Controlled Trials (Central). Weighted mean difference (WMD) and relative risk (RR) were used to evaluate clinical outcomes. Indirect treatment comparison (ITC) software was used to conduct indirect treatment comparison.Results: Ten studies were pooled with 6,325 patients in our meta-analysis. Both botulinum toxin and CGRP monoclonal antibody demonstrated favorable efficacy in the change of migraine days, headache days, HIT-6 score, and 50% migraine responder rate compared with placebo. In indirect treatment comparison, CGRP monoclonal antibody was superior to botulinum toxin in the frequency of acute analgesics intake (WMD = −1.31, 95% CI: −3.394 to 0.774, p = 0.02113), the rate of treatment-related adverse events (AEs) (RR = 0.664, 95% CI: 0.469 to 0.939, p = 0.04047), and the rate of treatment-related serious adverse events (RR = 0.505, 95% CI: 0.005 to 46.98, p < 0.001).Conclusion: For chronic migraine patients, CGRP monoclonal antibody was slightly better than botulinum toxin in terms of efficacy and safety. In the future, head-to-head trials would be better to evaluate the efficacy and safety between different medications in the prevention of chronic migraine.
Objective To explore the effects of valproate on vestibular migraine(VM)symptom improvement and vestibular function.Methods The patients with VM treated in the Dizziness Diagnosis and Treatment Center of The Sec-ond Affiliated Hospital of Naval Medical University from September 1,2019 to May 1,2021 were randomly divided into Valproate group and Flunarizine group.The patients were treated with valproate or flunarizine for three months.Before and after the treatment,the frequency of VM as well as the scores of Visual Analogue Scale(VAS)and Dizziness Handi-cap Inventory(DHI)items were recorded.Vestibular function was compared in the Valproate group before and after treat-ment.Results The VM frequency,the total scores of VAS and DHI,and the scores of VAS and DHI items in both groups were significantly reduced after the treatment.The changes in VM frequency,VAS score,DHI-F score,DHI-P score,and total DHI score before and after treatment were significantly greater in the Valproate group than in the Flunari-zine group.There was no significant difference in the variation of DHI-E score before and after treatment between the two groups.Abnormal eye movement,gaze,and spontaneous nystagmus decreased significantly in the Valproate group after treatment.There were no significant differences in abnormal caloric test,c-VEMP,o-VEMP,saccade test,smooth pursuit test,and direction-changing positional nystagmus.Conclusion Valproate can significantly improve the symptoms of VM and reduce its frequency.Valproate is more efficient than flunarizine.
Myasthenia gravis is an autoimmune disease,which is usually mediated by antibodies to acetylcholine re-ceptors at the neuromuscular junction.It is commonly treated with cholinesterase inhibitors such as pyridostigmine bro-mide.Although cardiovascular events with the drug are rare,it is very important to early recognize disease changes and be alert to potential cardiovascular events in patients with myasthenia gravis.Therefore,we report a case of an elderly female patient with myasthenia gravis developing acute myocardial infarction and then sudden cardiac death following anticholines-terase therapy,and discuss the possible causes of adverse cardiovascular events based on this case.